Zedsen Limited

In 2022 2.3M people were diagnosed with breast cancer (BC), globally, with roughly 670,000 deaths. In the five-year period before this, there were 7.8M cases, making it the most prevalent cancer globally. Current breast cancer screening techniques in the UK are imperfect, expensive, painful, subject to operator variability, fail to work in dense breast ti...

Although the biggest cause of premature female death, if diagnosed early breast cancer is curable. Zedsen is therefore developing a unique, wearable device which contains completely harmless next-generation sensors. It will be low cost, completely safe and will be both quick and simple to use. A smart phone will remind the owner once a month to wear the d...

Medical imaging has an important role in every medical setting as effective decisions depend on a correct diagnosis. However current technology (i.e. x-ray & MRI) is expensive, and requires strict safety measures and compatible equipment to avoid serious injury to patients and staff from radiation. Zedsen have developed a portable sensor that can overcome...

Cranfield University: Cranfield is the postgraduate specialist for research and teaching in science, engineering, technology and management. As one of the top five research-intensive universities in the UK, we are making a significant difference in the real world and we do this by working in partnership with some of the world's greatest organisations.